Entrada Therapeutics (TRDA)
(Real Time Quote from BATS)
$14.22 USD
-0.53 (-3.59%)
Updated Aug 5, 2024 01:24 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
TRDA 14.22 -0.53(-3.59%)
Will TRDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRDA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TRDA
Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales
Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View
TRDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash
JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View
United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates
Other News for TRDA
REGENXBIO releases new data on DMD drug ahead of earnings
PepGen stock tumbles 25% following release of DMD drug data
Commit To Buy Entrada Therapeutics At $12.50, Earn 55.6% Annualized Using Options
Entrada Therapeutics’ ENTR-601-44 Shows Promising Phase 1 Results for DMD, Earns Buy Rating
Entrada Therapeutics price target lowered by $2 at H.C. Wainwright, here's why